Description:Rabbit anti-human Amyloid beta peptide 42 polyclonal antibody
Purification:Protein G affinity purified
Product Type:Primary antibody
Target Protein:Human Amyloid beta peptide 42
Immunogen:Synthetic full-length human amyloid beta peptide 42 (Ab42)
Specificity:This antibody recognizes human Abeta 42.
Reactivity: Human, others not tested
Host: Rabbit
Formulation:Lyophilized from a solution in 0.01M PBS, pH 7.2
Reconstitution:Double distilled water is recommended to adjust the final concentration to 1.00mg/mL.
Storage: Store at -20oC.Avoid repeated freeze/thaw cycles.
Research Area:Alzheimer’s disease and other neurodegenerative disease
Background:Amyloid beta peptide 42 (Ab42) is best known for its role in the formation of senile plaques in the brain of patients with Alzheimer’s disease. Ab42 and Ab40 are the two major amyloid peptides that are produced after cleavage of amyloid precursor protein by secretases. Ab42 (42 amino acids) is very fibrillogenic. The beta pleated structure of Ab42 constituents the initial and key component of the insoluble amyloid fibril in senile plaque. It is widely accepted that Ab42 contributes to the pathogenesis of Alzheimer’s disease. One proposition is that the deposition of amyloid fibril onto the brain tissue results in Alzheimer’s disease. Another is that the neurotoxicity of Ab42 oligomer is the cause of the disease.
Applications:
Indirect ELISA:The antibody is reactive to full-length human Ab42 in indirect ELISA. It has not been evaluated in sandwich ELISA assay.
References:
If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.
Product Specificity | pAb Rabbit anti-Human Amyloid beta peptide 42 |
---|---|
Application | EIA |
Size | 0.1 mg |
Anogen-Yes Biotech Laboratories Ltd.是一家位于加拿大密西沙加的生物技术公司。成立于1989年,我们30年来一直是高质量抗体基产品的骄傲供应商。我们提供300多种单克隆和多克隆抗体,以及60多种类型的ELISA试剂盒,用于研究,诊断和治疗应用。
作为一家专注于研究的公司,我们还开发了许多专有的诊断和治疗产品。我们的产品Abcream是一种有效的抗牛皮癣局部抗IL-8(CXCL8)单克隆抗体,已于2001年获得中国国家食品药品监督管理局(SFDA)的批准,并获得多项国际专利。我们的用于诊断目的的新生儿TSH ELISA试剂盒也已获得加拿大卫生部的许可。我们还启动了针对炎症,阿尔茨海默氏病和癌症的研究和开发产品。